12 December 2024

Corp

Ticker	PMG:AIM
Oil & Gas	
Shares in issue (m)	109.3
Next results	H1 May
Price	13.8p
Target price	66.5p
Upside	383%
Market Cap	£15.0m
Net debt/(cash)	-£11.8m
Other EV adjustments	£0.0m
Enterprise value	£3.3m

What's changed?	From	То
Adjusted EPS	-	n/c
Target price	66.5	n/c

Share price performance



%	1M	3M	12M
Actual	17.0	35.8	-3.5

Company description

Parkmead has four divisions offering a broad set of growth opportunities in oil, gas and renewables.

James McCormack

Director of Research jmccormack@cavendish.com 020 7397 8915

John-Marc Bunce

Director of Research jbunce@cavendish.com 020 7397 8918

Sales desk 020 7397 1930

Trading desk 020 7220 0533

* denotes corporate client of Cavendish

Parkmead Group*

Sale of two UK Offshore Oil Licences

Parkmead has signed an agreement to sell its UK offshore oil portfolio to Serica Energy in a deal that could be worth up to £134m. Whilst the headline consideration consists of £14m of firm cash consideration and up to £120m of contingent cash consideration (linked to the development of the Skerryvore and Fynn Beauly projects), the actual firm value to Parkmead is c£30m, and includes the estimated £16m liability associated with the drilling of the Skerryvore commitment well (planned for Q3/Q4 2025). The deal removes any risk or further financial commitment for Parkmead to either development whilst also allowing the Company to retain a significant share of the upside should either/both developments proceed. Importantly, the transaction allows Parkmead to retain all its revenue generating assets, comprising its Dutch natural gas fields and its UK wind farm. The near-term cash consideration of £14m puts Parkmead in a strong financial position to pursue future growth, without the need for shareholder dilution.

- Rationale Given the potential capital requirements needed to progress Skerryvore (including the Skerryvore commitment well in Q3/Q4 2025) and Fynn Beauly through appraisal and development and the ongoing political and environmental headwinds towards the oil & gas industry in the UK, Parkmead believes that the opportunity to progress its UK North Sea oil & gas licences would be best served within the portfolio of a larger, North Sea focussed company, enabling Parkmead to apply its expertise and the Company's resources on growing its Netherlands gas assets and its projects in renewable energies.
- No Risk, High Upside Value The consideration for the sale consists of £14m of firm cash consideration and up to £120m of contingent cash consideration. An initial payment of £5m is payable on completion of the sale (expected 1H25). Three further deferred firm payments totalling £9m are payable in instalments of £2.0m, £3.1m and £3.9m on the 27 February 2025, 27 February 2026 and 27 February 2027, respectively. Two contingent payments are payable upon receipt by Serica of approval by the North Sea Transition Authority of any field development plan (FDP) relating to any development on licence P2400 (containing the Skerryvore prospect) or licence P2634 (containing the Fynn Beauly oil discovery). These payments are to be calculated based on £0.8/bbl of the 2P reserves contained within the respective FDP net to Parkmead's 50% working interest in each licence, subject to caps of £30m (in relation to licence P2400) and £90m (in relation to licence P2634).
- Future Strategy In the Netherlands, the co-venturers are working to identify and develop several short cycle, rapid payback drilling and workover opportunities. The team is also continuing to progress a joint venture agreement for a major wind farm of up to 100MW centred around the Company's owned land at Pitreadie. The Company is also well positioned to pursue value-adding acquisition opportunities, specifically further cashflow generating renewable energy assets onshore UK and international E&P opportunities with the aim of delivering value for shareholders.
- Valuation We update our valuation pro-rata the completion of the Serica transaction, removing Parkmead's UK offshore oil and gas assets and liabilities, and adding in the firm and contingent consideration. We maintain our valuation and target price at 66.5p, representing a 383% premium to yesterday's close.

Key estimates		2020A	2021A	2022A	2023A	2024A
Year end:		Jun	Jun	Jun	Jun	Jun
Revenue	£m	4.1	3.6	12.1	14.8	5.7
Adj EBITDA	£m	0.3	-0.9	8.2	-21.5	2.4
Adj EBIT	£m	-0.5	-1.5	7.5	-22.2	1.4
Adj PBT	£m	-0.7	-2.6	6.3	-22.3	1.1
Adj EPS	р	0.5	-2.2	1.2	3.0	4.1
DPS	р	0.0	0.0	0.0	0.0	0.0

Key valuation metri	cs					
EV/sales	X	0.8	0.9	0.3	0.2	0.6
EV/EBIT (adj)	X	-6.7	-2.1	0.4	-0.1	2.4
P/E (adj)	X	30.2	-6.2	11.7	4.6	3.4
Dividend yield	%	0.0%	0.0%	0.0%	0.0%	0.0%
Free cash yield	%	-31.5%	-13.2%	-6.0%	-72.6%	-8.1%

Cavendish is the trading name for business conducted by Cavendish Capital Markets Limited, Cavendish Securities plc and Cavendish Corporate Finance LLP. Cavendish produces non-independent research which is a marketing communication under the Markets In Financial Instruments Directive and the Financial Conduct Authority's Handbook Conduct of Business (COBS) rules. Accordingly, this document has not been prepared in accordance with legal requirements to promote independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Cavendish Capital Markets Limited (FCA registered no. 467766), Cavendish Securities plc (FCA registered no. 416932) and Cavendish Corporate Finance LLP (FCA registered no. 474794) are authorised and regulated by the Financial Conduct Authority and are members of the London Stock Exchange. Registered office: 1 Bartholomew Close, London EC1A 7BL.

Income statement		2021A	2022A	2023A	2024A
Year end:		Jun	Jun	Jun	Jun
Sales	£m	3.6	12.1	14.8	5.7
Gross profit	£m	2.3	11.6	13.3	4.5
EBITDA (adjusted)	£m	-0.9	8.2	-21.5	2.4
EBIT (adjusted)	£m	-1.5	7.5	-22.2	1.4
Associates/other	£m	-0.4	0.0	0.0	0.0
Net interest	£m	-0.7	-1.2	-0.1	-0.3
PBT (adjusted)	£m	-2.6	6.3	-22.3	1.1
Total adjustments	£m	-10.9	-2.3	-13.0	-0.0
PBT (stated)	£m	-13.5	4.0	-35.3	1.1
Tax charge	£m	-0.4	-4.8	-7.0	3.9
Minorities/Disc ops	£m	0.0	0.0	0.0	0.0
Reported earnings	£m	-13.8	-0.8	-42.3	4.9
Adjusted earnings	£m	-2.6	1.4	3.6	4.9
Shares in issue (year end)	m	109.2	109.3	109.3	109.3
EPS (stated)	р	-12.7	-0.7	-38.7	4.5
EPS (adjusted, fully diluted)	р	-2.2	1.2	3.0	4.1
DPS	р	0.0	0.0	0.0	0.0

Cash flow		2021A	2022A	2023A	2024A
Year end:		Jun	Jun	Jun	Jun
EBITDA	£m	-0.9	8.2	-21.5	2.4
Net change in working capital	£m	-1.1	-0.6	0.0	-0.9
Other operating items	£m	0.8	0.4	32.9	-0.0
Cash flow from op. activities	£m	-1.2	8.0	11.4	1.5
Cash interest	£m	0.0	0.0	0.1	-0.1
Cash tax	£m	-0.1	-3.5	-4.9	0.8
Capex	£m	-0.7	-3.8	-0.5	-0.6
Other items	£m	-0.0	-1.7	-17.0	-2.8
Free cash flow	£m	-2.0	-0.9	-10.9	-1.2
Acquisitions / disposals	£m				
Dividends	£m				
Shares issued	£m	0.0	0.0	0.0	0.0
Other	£m	-4.4	-0.1	-0.4	-0.3
Net change in cash flow	£m	-2.4	-0.1	-11.7	-2.1
Opening net cash (debt)	£m	25.0	25.8	25.2	13.7
Closing net cash (debt)	£m	25.8	25.2	13.7	11.8

Balance sheet		2021A	2022A	2023A	2024A
Year end:		Jun	Jun	Jun	Jun
Tangible fixed assets	£m	19.3	22.5	10.1	9.7
Goodwill & other intangibles	£m	31.7	35.4	3.1	3.6
Other non current assets	£m	2.9	3.1	0.0	0.0
Net working capital	£m	-2.1	-20.7	-1.6	-0.2
Other assets	£m	0.0	0.0	2.9	2.9
Other liabilities	£m	-17.0	-5.6	-10.5	-5.1
Gross cash & cash equivs	£m	23.4	23.3	11.6	9.5
Capital employed	£m	58.2	57.9	15.5	20.3
Gross debt	£m	0.5	0.9	0.9	0.7
Net pension liability	£m	0.0	0.0	0.0	0.0
Shareholders equity	£m	57.7	57.0	14.7	19.6
Minorities	£m	0.0	0.0	0.0	0.0
Capital employed	£m	58.2	57.9	15.5	20.3

Growth analysis		2021A	2022A	2023A	2024A
Year end:		Jun	Jun	Jun	Jun
Sales growth	%	-11.6%	236.1%	21.8%	-61.3%
EBITDA growth	%	-430.6%	n/m	-361.5%	111.2%
EBIT growth	%	-212.2%	592.2%	-396.4%	106.2%
PBT growth	%	-248.5%	342.2%	-456.6%	105.0%
EPS growth	%	-589.6%	152.6%	156.4%	35.4%
DPS growth	%	n/m	n/m	n/m	n/m

Profitability analysis		2021A	2022A	2023A	2024A
Year end:		Jun	Jun	Jun	Jun
Gross margin	%	64.9%	95.4%	89.7%	78.4%
EBITDA margin	%	-25.3%	67.8%	-145.6%	42.1%
EBIT margin	%	-42.2%	61.8%	-150.5%	24.1%
PBT margin	%	-71.6%	51.6%	-151.0%	19.5%
Net margin	%	-73.3%	11.5%	24.1%	86.4%

Valuation analysis		2021A	2022A	2023A	2024A
Year end:		Jun	Jun	Jun	Jun
EV/EBITDA	Х	-3.6	0.4	-0.2	1.4
EV/EBIT	Х	-2.1	0.4	-0.1	2.4
P/E	x	-6.2	11.7	4.6	3.4

Cash flow analysis		2021A	2022A	2023A	2024A
Year end:		Jun	Jun	Jun	Jun
Cash conv'n (op cash / EBITDA)	%	n/m	97.7%	n/m	63.0%
Cash conv'n (FCF / EBITDA)	%	217.7%	-10.9%	50.7%	-50.4%
U/lying FCF (capex = depn)	£m	-1.9	2.2	-11.1	-1.6
Cash quality (u/l FCF / adj earn)	%	72.5%	155.6%	-311.7%	-33.1%
Investment rate (capex / depn)	Х	1.1	5.2	0.7	0.6
Interest cash cover	Х	net cash	n/a	n/a	21.4
Dividend cash cover	х	n/a	n/a	n/a	n/a

Working capital analysis		2021A	2022A	2023A	2024A
Year end:		Jun	Jun	Jun	Jun
Net working capital / sales	%	-57.4%	-170.8%	-11.0%	-4.3%
Net working capital / sales	days	-210	-623	-40	-16
Inventory (days)	days	7	1	0	0
Receivables (days)	days	137	61	23	104
Payables (days)	days	353	685	64	120

Leverage analysis		2021A	2022A	2023A	2024A
Year end:		Jun	Jun	Jun	Jun
Net debt / equity	%	net cash	net cash	net cash	net cash
Net debt / EBITDA	Х	n/a	net cash	n/a	net cash
Liabilities / capital employed	%	0.9%	1.6%	5.5%	3.3%

Capital efficiency & intrinsic value		2021A	2022A	2023A	2024A
Year end:		Jun	Jun	Jun	Jun
Adjusted return on equity	%	-4.6%	2.4%	24.3%	25.2%
RoCE (EBIT basis, pre-tax)	%	-2.6%	12.9%	-143.2%	6.8%
RoCE (u/lying FCF basis)	%	-3.3%	3.7%	-71.6%	-8.1%
NAV per share	р	52.9	52.2	13.4	18.0
NTA per share	р	23.9	19.7	10.6	14.7

Sale of Parkmead (E&P)

Parkmead has signed an agreement with Serica Energy (UK) Limited for the sale of the Company's wholly owned subsidiary Parkmead (E&P) Ltd.

The subsidiary currently holds Parkmead's UK offshore oil licences together with its Netherlands onshore gas licences. The Netherlands asset portfolio is excluded from the scope of the transaction and will be retained by the Group. Therefore, Parkmead is retaining 100% of its revenue producing assets, which comprise its Dutch natural gas fields and its UK wind farm, all of which are onshore.

Reducing capital requirements whilst retaining upside

Through the sale of Parkmead's UK offshore oil business, Parkmead has no further capital investment requirements, but retains a very attractive share of the upside should developments at Skerryvore and/or Fynn Beauly proceed.

The consideration for the sale being received by Parkmead consists of £14m of firm cash consideration and up to £120m of contingent cash consideration:

- An initial payment of £5m, payable at completion of the sale.
- Three further deferred payments totalling £9m, payable in instalments of £2.0m, £3.1m and £3.9m on 27 February 2025, 27 February 2026 and 27 February 2027, respectively. These future payments are firm and not subject to any conditions.
- Two contingent payments, payable upon receipt by Serica of approval by the North Sea Transition Authority (NSTA) for any field development plan (FDP) relating to any development on licence P2400 (containing the Skerryvore prospect) or licence P2634 (containing the Fynn Beauly oil discovery). These payments are to be calculated based on £0.8/bbl of the 2P reserves contained within the respective FDP net to the Subsidiary's current 50% working interest in each licence, subject to caps of £30 million (in relation to licence P2400) and £90 million (in relation to licence P2634).

Figure 1: Consideration Overview	
Initial Payment	£5m
Deferred Payments	£9m
Total Firm Consideration	£14m
Contingent Skerryvore Payment	Up to £30m
Contingent Fynn Beauly Payment	Up to £90m
Total Contingent Consideration	Up to £120m
Total Consideration (Firm and Contingent)	Up to £134m

Source: The Parkmead Group

Whilst the headline consideration consists of £14m of firm cash consideration and up to £120m of contingent cash consideration, the actual firm value to Parkmead is c£30m, and includes the estimated £16m liability associated with the drilling of the Skerryvore commitment well (planned for Q3/Q4 2025).

Given the potential capital requirements needed (including the near-term drilling of the Skerryvore well in 2025) to progress the Skerryvore and Fynn Beauly assets through appraisal and development and the continuing political and environmental headwinds facing the UK oil & gas sector, Parkmead believes that the opportunity to progress both licences would be best served within the portfolio of a larger, North Sea focused company, enabling Parkmead to apply its expertise and the Company's resources on growing its Netherlands gas assets and its projects in renewable energies.

The sale removes any risk to Parkmead from either the Skerryvore or the Fynn Beauly projects, whilst also retaining an attractive portion of the potential upside should either/both projects reach FDP approval.

Well-funded without shareholder dilution

The firm, near-term cash consideration totalling £14m, together with Parkmead's existing cash means the Group is well funded to pursue the next phase of its growth plans in natural gas, renewables and international E&P.

In the Netherlands, the co-venturers are working to identify and develop a number of short-cycle, rapid payback drilling and workover opportunities. The Parkmead team is also progressing a JV agreement for a major wind farm of up to 100MW centred around the Company's owned land at Pitreadie.

Parkmead is also well positioned to pursue value-adding acquisition opportunities. The Board is focused on targeting the acquisition of further cashflow generating renewable energy assets onshore UK and on international E&P opportunities with the aim of delivering value for shareholders.

Valuation

We update our valuation to remove all Parkmead's UK offshore oil assets (e.g. Lowlander/Midlander, Fynn Beauly and Fynn Andrew in P2634 and Skerryvore in P2400). We have also removed Parkmead's decommissioning liabilities from our valuation and the NPV of its UK tax losses.

We have added the firm payments of £14m and the contingent payments for Skerryvore and Fynn Beauly to our valuation, risking both contingent payments in-line with our previous risking for Skerryvore (7% chance of success) and Fynn Beauly (30% chance of success). We note that this approach is conservative as our previous risking was based on both projects commencing production, whereas for Parkmead to be paid its contingent consideration the projects only have to reach FDP approval.

We maintain our valuation at 66.5p, a 383% premium to yesterday's closing price.

Net Asset Valuation	Net resource	NPV/bbl	Unrisk	ed NPV	Geological	Commercial	Dry hole	Riske	d NPV
	mmboe	US\$/boe	US\$m	p/sh	CoS	CoS	cost US\$m	US\$m	p/sh
Net cash / (debt)			14.1	9.7				14.1	9.7
G&A			-13.0	-8.9				-13.0	-8.9
Options/SARs			4.4	3.0				4.4	3.0
Serica Energy Initial Cash Payment			6.0	4.1				6.0	4.1
Serica Energy Deferred Payments			10.8	7.4				10.8	7.4
Serica Energy Contingent Skerryvore Paymen	it		36.0	24.7	24%	30%		2.6	1.8
Serica Energy Contingent Fynn Beauly Payme	ent		108.0	74.2	100%	30%		32.4	22.3
Pitreadie Farm Ltd land (@ cost adjusted for la	and sales)		5.4	3.7				5.4	3.7
			171.7	117.9				62.7	43.1
Producing assets									
Kempstone Hill 1.5MW Wind Farm			4.3	3.0		100%		4.3	3.0
Netherlands producing	0.5	6.54	3.3	2.3	100%	100%		3.3	2.3
Core value:			179.4	123.2				70.4	48.3
Contingent resource:									
Netherlands - Papekop	0.8	8.57	6.7	4.6	100%	75%		5.0	3.5
Netherlands - Ottoland	0.7	8.57	5.9	4.1	100%	50%		3.0	2.0
Contingent value:			12.6	8.7				8.0	5.5
Prospective resource:									
Netherlands - Drenthe VI prospects	2.0	8.57	17.4	12.0	37%	75%	4.7	2.4	1.6
Prospective value:			17.4	12.0			4.7	2.4	1.6
Renewables developments:	US\$/MW	IRR %							
Pitreadie 20MW Wind Farm	0.90	19.6%	18.0	12.4		40%		7.2	4.9
Pitreadie 50MW Solar Farm	0.67	12.2%	13.4	9.2		40%		5.4	3.7
Brachmonth 30MW Solar Farm	0.44	12.1%	8.7	6.0		40%		3.5	2.4
Renewables development value:			40.1	27.6				16.0	11.0
Total - Core + Contingent + Prospective + Re	newables:		249.6	171.4				96.8	66.5

Source: Cavendish

Investment risk

Investing in shares presents risks and opportunities. The past is not necessarily a guide to the future performance of an investment. The value of investments and the income derived from them may fall as well as rise and investors may not get back the amount invested. Some investments discussed in this publication may have a high level of volatility. High volatility investments may experience sudden and large falls in their value which may cause losses. The information on future performance in this communication is an illustration and is not a reliable guide to actual future performance.

Non-UK stocks

International investing includes risks related to political and economic uncertainties of foreign countries, as well as currency risk.

Disclosures

Analyst certification

The Sales Person(s) / Research Analyst(s) responsible for preparing this investment recommendation/report or sections of this report, in whole or in part, hereby certify/ies that, with respect to any and all of the securities or issuers that the Sales Person(s) / Research Analyst(s) cover(s) in this report, the views expressed in this report accurately reflect his/her/their personal views. However, this investment recommendation / report may have been disclosed to the issuer prior to its publication and may have been subject to amendment thereafter. The proprietary models used in production of this investment recommendation are available on request. It is intended that the proprietary models used in this investment recommendation shall be updated when appropriate. In addition, no part of the Sales Person(s) / Research Analyst(s)' compensation was, is, or will be directly or indirectly, related to the specific recommendations or view expressed in this report or summary.

Recommendations definitions

Definition of research recommendations

Expected absolute returns

BUY is an expected return greater than 10%

HOLD is an expected return -10% - +10%

SELL is an expected return less than -10%

UNDER REVIEW: recommendation and/or forecasts are under review pending further clarity as to the company's financial and/or operational position

CORP: denotes corporate client of Cavendish Securities plc, Cavendish Capital Markets Limited and Cavendish Corporate Finance LLP

For Sales recommendation please refer to https://www.cavendish.com

Distribution of investment recommendations as per 11/12/2024

	Corporate client no.	Corporate client %	Total no.	Total %
Buy	2	1.4%	20	12.1%
Hold	0	0.0%	1	0.6%
Sell	0	0.0%	0	0.0%
Under Review	0	0.0%	0	0.0%
Corp	134	96.4%	144	87.3%

Temporary movements by stocks across the boundaries of these categories due to share price volatility will not necessarily trigger a recommendation change. All recommendations are based on 12-month time horizon unless otherwise stated.

Recommendation history

Company	Disclosures	Date	Rec	Price	Target price
Parkmead Group	2,6,8,9,10,11	20 November 20	Corp	30.0p	155.0p
Source: Cavendish					

A list of all the recommendations produced/issued by the relevant Sales Person / Research Analyst on any financial instrument or issuer disseminated during the preceding 12 months is available upon request free of charge. Please contact the appropriate Cavendish analyst or your Cavendish contact on 020 7220 0500.

Legend

- 1. The Sales / Research Analyst persons closely associated with them and/or persons involved in the preparation of the investment recommendation, has a beneficial interest in the shares of this issuer. This holding(s) was not received or purchased prior to a public offering of such shares.
- 2. The Sales / Research Analyst responsible for this investment recommendation may have his/her remuneration linked to investment banking transactions performed by Cavendish.
- A director, officer or employee of Cavendish or a person closely associated to him/her, is an officer, director, or serves as an adviser or board member of the issuer. Where this person is the
 person responsible for this investment recommendation or a person closely associated with them, this will be indicated.
- 4. As at the date of this investment recommendation / report, Cavendish has a beneficial interest exceeding 5% of the total issued share capital in the issuer.
- 5. As at the date of this investment recommendation / report, the issuer has a beneficial interest exceeding 5% of the total issued share capital of Cavendish.
- 6. Cavendish acts as a market maker or liquidity provider in relation to securities issued by the issuer.
- 7. Cavendish has been the lead manager or co-lead manager in a public offering of the issuer's financial instruments during the previous 12 months.
- 8. Cavendish is party to an agreement with the issuer and has received compensation from the issuer for the provision of investment banking or financial advisory services within the previous 12 months.
- 9. Cavendish is party to an agreement with the issuer relating to the provision of investment recommendations for this issuer and Cavendish may receive remuneration for such service.
- 10. Cavendish acts as a corporate broker to this issuer.
- 11. Cavendish acts as a nominated adviser, financial adviser or as a sponsor to the issuer in the UK.
- 12. As at the date of this investment recommendation, Cavendish has a net short position exceeding 0.5% of the total issued share capital of the issuer.
- 13. As at the date of this investment recommendation, Cavendish has a net long position exceeding 0.5% of the total issued share capital of the issuer.
- 14. Any other specific disclosures.

Disclaimer

This communication is NON-INDEPENDENT RESEARCH AND A MARKETING COMMUNICATION under the FCA's Conduct of Business Sourcebook (COBS) and is issued in the UK by Cavendish, the trading name for the business operated by Cavendish Capital Markets Limited, Cavendish Securities plc and Cavendish Corporate Finance LLP, which are authorised and regulated by the Financial Conduct Authority (FCA) and are members of the London Stock Exchange. Non-independent research has not been prepared in accordance with the legal requirements to promote independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Cavendish considers that this communication constitutes an acceptable minor non-monetary benefit in accordance with chapter 2.3A.19 R (5) (b) or (g) of COBS as appropriate.

This document and any investment to which this document relates is intended for the sole use of the persons to whom it is addressed and is for distribution in the United Kingdom only to 'professional clients' or 'eligible counterparties' within the meaning of chapter 3 of COBS or persons described in Articles 19(5) (Investment professionals) or 49(2) (High net worth companies, unincorporated associations etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) ('FPO') and all other exempt persons under the FPO (all such persons together being referred to as 'Relevant Persons'). It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons and may not be relied upon by such persons and is therefore not intended for private individuals or those who would be classified as retail clients under COBS. This document is directed only at Relevant Persons. Other persons should not act or rely on this document or any of its contents. Laws and regulations of other countries may also restrict the distribution of this report. Persons in possession of this document should inform themselves about possible legal restrictions and observe them accordingly. Any investment to which this document relates is available only to such persons, and other classes of person should not rely on this document.

This document has been prepared and issued by Cavendish on the basis of publicly available information, internally developed data and other sources believed to be reliable. Share price performance graphs are sourced from Morningstar, FactSet, Proquote International and Thomson Reuters Datastream. The information contained in this publication was obtained from various sources believed to be reliable, but has not been independently verified by Cavendish. Cavendish does not warrant the completeness or accuracy of such information and does not accept any liability with respect to the accuracy or completeness of such information, except to the extent required by applicable law. Any opinions, projections, forecasts or estimates in this report are those of the author only, who has acted with a high degree of expertise. They reflect only the current views of the author at the date of this report and are subject to change without notice. Cavendish has no obligation to update, modify or amend this publication or to otherwise notify a reader or recipient of this publication in the event that any matter, opinion, projection, forecast or estimate contained herein, changes or subsequently becomes inaccurate, or if research on the subject company is withdrawn. The analysis, opinions, projections, forecasts and estimates expressed in this report were in no way affected or influenced by the issuer. The author of this publication benefits financially from the overall success of Cavendish.

This publication is a brief summary and does not purport to contain all available information on the subjects covered. Further information may be available on request. This report may not be reproduced for further publication without the prior written permission of Cavendish. This publication is for information purposes only and shall not be construed as an offer or solicitation for the subscription or purchase or sale of any securities, or as an invitation, inducement or intermediation for the sale, subscription or purchase of any securities, or for engaging in any other transaction. The investments referred to in this publication may not be suitable for all recipients. Recipients are urged to base their investment decisions upon their own appropriate investigations that they deem necessary. Any loss or other consequence arising from the use of the material contained in this publication shall be the sole and exclusive responsibility of the investor and Cavendish accepts no liability for any such loss or consequence. In the event of any doubt about any investment, recipients should contact their own investment, legal and/or tax advisers to seek advice regarding the appropriateness of investing. Some of the investments mentioned in this publication may not be readily liquid investments. Certain transactions, including those involving futures, options, and high yield securities, give rise to substantial risk and are not suitable for all investors. Investors should be aware of the additional and special risks associated with securities and investments in emerging markets. Consequently, it may be difficult to sell or realise such investments. The past is not necessarily a guide to future performance of an investment. The value of investments and the income derived from them may fall as well as rise and investors may not get back the amount invested. Some investments discussed in this publication may have a high level of volatility. High volatility investments may experience sudden and large falls in their value whi

Cavendish has written procedures designed to identify and manage potential conflicts of interest that arise in connection with its research business and its production. Cavendish's research analysts and other staff involved in issuing and disseminating research reports operate independently of Cavendish's Corporate Finance business. Information barriers procedures are in place between the Sales and Research Analysts and staff involved in securities trading for the account of Cavendish or its clients to ensure that inside information is handled according to applicable laws and regulations.

Cavendish may be remunerated by a company for writing research on that company, in which case, a specific disclosure will be made in the relevant research report. Each company understands and agrees that the analysis, opinions, projections, forecasts and estimates expressed in such research reports will be honest and unbiased in compliance with Cavendish's Conflicts of Interests and Research Policies and will in no way be influenced by any remuneration received by Cavendish from the company. For further details, please see Cavendish's Conflicts of Interest Policy available on our website at www.cavendish.com.

Cavendish Capital Markets Limited, Cavendish Securities plc and Cavendish Corporate Finance LLP are incorporated and principally operate in England and Wales. Cavendish is not registered as a broker-dealer in the US and relies on the exemption in Rule 15a-6 under the Securities Exchange Act of 1934 when interacting with US persons. For the purposes of this exemption, please note that this publication should not be construed as an invitation, inducement, solicitation or intermediation for the sale, subscription or purchase of any securities or for engaging in any other transaction. Cavendish Capital Markets Limited and its assets are regulated in England and Wales by the FCA (registered number 467766), Cavendish Securities plc and its assets are regulated in England and Wales by the FCA (registered number 416932) and Cavendish Corporate Finance LLP and its assets are regulated in England and Wales by the FCA (registered number 474794). Accordingly, laws, regulations and remedies may differ to those available in the US.

Cavendish is not registered in any Canadian jurisdiction but operates in Canada using the International Dealer and/or Adviser exemption granted by the Ontario Securities Commission, the British Columbia Securities Commission and the AMF in Québec under section 8.18 and/or 8.26 of NI31-103. Laws, regulations and remedies may differ to those available in Canada accordingly.

This document may be distributed to wholesale clients in Australia in reliance on relief pursuant to ASIC Class Order CO 03/1099.

For Entities and Clients in the United States

Cavendish Securities Ltd is not registered as a broker-dealer with the US Securities and Exchange Commission, and it and its analysts are not subject to SEC rules on securities analysts' certification as to the currency of their views reflected in the research report. Cavendish is not a member of the Financial Industry Regulatory Authority. It and its securities analysts are not subject to FINRA's rules on Communications with the Public and Research Analysts and Research Reports and the attendant requirements for fairness, balance and disclosure of potential conflicts of interest.

This research report is only being offered to US Institutional Investors via our US chaperoning broker Auerbach Grayson and Company and is not available to, and should not be used by, any US person or entity that is not a US Institutional Investor. Cavendish cannot and will not accept orders for the securities covered in this research report placed by any person or entity in the United States. Orders should be placed with our correspondent. Auerbach Grayson & Company at 212-557-4444.

A Major US Institutional Investor who may receive and use this report must have assets under management of more than US\$100,000,000 and is either an investment company registered with the SEC under the US Investment Company Act of 1940, a US bank or savings and loan association, business development company, small business investment company, employee benefit plan as defined in SEC Regulation D, a private business development company as defined in SEC Regulation D, an organisation described in US Internal Revenue Code Section 501(c)(3) and SEC Regulation D, a trust as defined in SEC Regulation D, or an SEC registered investment adviser or any other manager of a pooled investment vehicle.

www.cavendish.com